FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* NAVARRE CHRISTOPHE (Last) (First) (Middle) BLOCK 10-1, BLANCHARDSTOWN							Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC [AVDL] 3. Date of Earliest Transaction (Month/Day/Year) 06/28/2017								Relationship of Reporting Person(s) to Issuer neck all applicable) X Director 10% Owner Officer (give title below) below)		
(Street) DUBLIN L2 15 (City) (State) (Zip)					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D							ction 2A. Deemed Execution Date			ion I	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5) Amount (A) or (D) Pri		ed (A) or tr. 3, 4 and	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		(e.g., p							nvertib ole and	or Beneficially le securities) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
				C	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares				
Warrants (right to buy) ⁽¹⁾	\$14.54 ⁽¹⁾								06/24/2015 ⁽³	1) 06	6/24/2018	ADSs ⁽²⁾	46,000		46,000	D	
Warrants (right to buy ⁽³⁾	\$21.67 ⁽³⁾								06/26/2016 ⁽³	3) 06	6/26/2019	ADSs ⁽²⁾	54,026		54,026	D	
Warrants (right to buy) ⁽⁴⁾	\$13.59 ⁽⁴⁾								08/10/2017 ⁽	4) 08	8/17/2020	ADSs ⁽²⁾	54,026		54,026	D	
Stock Option (right to	\$10.51 ⁽⁵⁾	06/28/2017			A		30,000		06/28/2018 ⁽⁵	5) 06	6/28/2022	ADSs ⁽²⁾	30,000	\$10.51	30,000	D	

Explanation of Responses:

- 1. Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 46,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
- 2. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary
- 3. Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 54,026 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS.
- 4. Warrants were granted 08/10/2016 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 54,026 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 54.026 ADSs vest on 08/10/2017.
- 5. Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date.

Remarks:

Remarks to Table I: No non-derivative securities are beneficially owned.

/s/ Phillandas T. Thompson, as attorney-in-fact for Christophe

06/30/2017

Navarre

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.